ASTH vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ASTH's Piotroski F-Score of 6/9 indicates a stable but not strong financial foundation, with notable weaknesses in profitability and cash flow generation. The absence of an Altman Z-Score raises concern about default risk, particularly given a high debt/equity ratio of 1.96 and negative earnings growth of -97.7% YoY. While the company exhibits explosive revenue growth (99.7% YoY) and strong earnings surprises in recent quarters, these are not sustainable without improving margins and profitability. The stock trades at a forward P/E of 9.64 but a current P/E of 107.00, suggesting a massive valuation disconnect that reflects overpricing relative to current earnings. The Graham Number of $8.19 and intrinsic value of $1.33 imply severe overvaluation, with the current price of $20.33 trading at a significant premium.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ASTH vs LLY: Head-to-Head Comparison
This page compares Astrana Health, Inc. (ASTH) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.